That which we call rosaimab by any other name would find regulatory approval and commercial success. Or would it?

How can smaller biopharma companies overcome the scale up and production complexities for microbial biomanufacturing?

What is going on with Aduhelm? And why is the drug seen by some to be controversial?

An industry consortium is tackling one of pharma’s biggest drug-related challenges.

A microfluidic bioprocessing company has set up shop in central Scotland. We spoke to their CEO for an inside view.

We want to hear your thoughts on what mRNA could do for cell and gene therapy

Are all antibiotics doomed to eventual impotence? New work from Oxford could change the game by defeating resistance itself.

Sitting Down With Dolores Schendel, Chief Executive Officer and Chief Scientific Officer at Medigene.

Get ready for medicine making level 2 as video games come to healthcare backed with clinical trial data that demonstrate efficacy.

Thorben Seeger wants to democratize the data held by the world’s leading genomic institutions. But what exactly does he mean by “democratize”?